Dublin, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The "Global HIV Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Sponsor - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The global market for HIV Clinical Trials is undergoing significant expansion, as demonstrated by fresh insights from a comprehensive research report that has recently been added to a renowned research database. This addition shines a spotlight on the intricate dynamics and growth prospects within this market over an extended forecast period from 2023 to 2030.
The report illuminates various sub-segments, offering a detailed examination of each to articulate the overarching landscape of the HIV Clinical Trials Market. In its meticulously segmented analysis, the report covers different clinical trial phases, study designs, sponsors, and regional insights to portray a panoramic view of the industry.
Market Dynamics and Predictions
Estimated at USD 985.25 Million in 2022 and expected to hit USD 1.05 Billion in 2023, the market is forecasted to reach a valuation of USD 1.79 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.76%. Among the phases of the clinical trials, Phase I has been spotlighted for its predicted notable share, indicative of the early stage investment in R&D for HIV treatments. Similarly, Expanded Access and Interventional Studies are anticipated to dominate the market based on study design.
Segmentation Insights
- Pharmaceutical and Biopharmaceutical Companies, as sponsors, are projected to hold a significant market share, heralding the critical role of these entities in driving forward HIV research and clinical trials.
- Geographically, the Americas have commanded the largest market share, with a focus on countries including the United States, Canada, and Brazil, among others. The report indicates a continuation of this trend with the EMEA region also showing promising market activity.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 196 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $1.05 Billion |
| Forecasted Market Value (USD) by 2030 | $1.79 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
Companies Mentioned
- Bionor Holding AS
- Charles River Laboratories
- Chiltern International Ltd.
- Eli Lilly and Company
- Gilead Sciences, Inc.
- GSK PLC
- ICON Plc
- IQVIA Inc.
- Janssen Global Services, LLC
- Novo Nordisk A/S
- Parexel International Corporation
- Pfizer, Inc.
- Pharmaceutical Product Development, LLC
- PRA Health Sciences
- SGS SA
- Syneos Health, Inc.
- Wuxi AppTec Inc.
For more information about this report visit https://www.researchandmarkets.com/r/uk143n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
